Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice

Maria L.H. Vlaming(Oncode Institute), Alfred H. Schinkel(Oncode Institute), Hilde Rosing(The Netherlands Cancer Institute), Liia D. Vainchtein(The Netherlands Cancer Institute), Ronald P.J. Oude Elferink(Amsterdam University Medical Centers), Dirk R. de Waart, Karin Mohrmann, Els Wagenaar(The Netherlands Cancer Institute), Jos H. Beijnen(The Netherlands Cancer Institute), Jan H.M. Schellens(Utrecht University), Jurjen S. Lagas, Olaf van Tellingen(Dutch Cancer Society)
Journal of Pharmacology and Experimental Therapeutics
April 13, 2006
10.1124/jpet.106.101774
Cited by 156

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884